Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD

We read with great interest in the article “A multi-society Delphi consensus statement on new fatty liver disease nomenclature” by international expert group.1 Since the name non-alcoholic fatty liver disease (NAFLD) was proposed, there have been lots of discussions about the nomenclature of fatty liver disease (FLD). A group of international experts issued a statement recommending that NAFLD could be renamed as metabolic dysfunction-associated fatty liver disease (MAFLD) in 2020.2 Three years later, the term metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed, and it can be diagnosed based on a patient meeting one of five cardiovascular risk factors, unlike MAFLD, which required that patients meet two of seven parameters of metabolic dysfunction.